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BRIEF REVIEW
Thrombus Structural Composition in 
Cardiovascular Disease
Ghadir Alkarithi, Cédric Duval, Yu Shi, Fraser L. Macrae , Robert A.S. Ariëns
ABSTRACT: Thrombosis is a major complication of cardiovascular disease, leading to myocardial infarction, acute ischemic 
stroke (AIS), or venous thromboembolism. Thrombosis occurs when a thrombus forms inside blood vessels disrupting blood 
flow. Developments in thrombectomy to remove thrombi from vessels have provided new opportunities to study thrombus 
composition which may help to understand mechanisms of disease and underpin improvements in treatments. We aimed to 
review thrombus compositions, roles of components in thrombus formation and stability, and methods to investigate thrombi. 
Also, we summarize studies on thrombus structure obtained from cardiovascular patients and animal models. Thrombi are 
composed of fibrin, red blood cells, platelets, leukocytes, and neutrophil extracellular traps. These components have been 
analyzed by several techniques, including scanning electron microscopy, laser scanning confocal microscopy, histochemistry, 
and immunohistochemistry; however, each technique has advantages and limitations. Thrombi are heterogenous in 
composition, but overall, thrombi obtained from myocardial infarction are composed of mainly fibrin and other components, 
including platelets, red blood cells, leukocytes, and cholesterol crystals. Thrombi from patients with acute ischemic stroke 
are characterized by red blood cell- and platelet-rich regions. Thrombi from patients with venous thromboembolism contain 
mainly red blood cells and fibrin with some platelets and leukocytes. Thrombus composition from patients with myocardial 
infarction is influenced by ischemic time. Animal thrombosis models are crucial to gain further mechanistic information about 
thrombosis and thrombus structure, with thrombi being similar in composition compared with those from patients. Further 
studies on thrombus composition and function are key to improve treatment and clinical outcome of thrombosis.
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Changes in clot structure are of key interest due to associations with risk of myocardial infarction (MI), acute ischemic stroke (AIS), and venous thrombo-
embolism (VTE). Most studies explored links between 
in vitro clot structure and thrombosis.1 Recent literature 
exceeds 1000 publications, with >400 in the past 5 
years alone.1–3 However, studies into the structure and 
components of thrombi formed in vivo remain limited. 
With the advent of new methodologies and imaging 
techniques, in vivo or ex vivo thrombi obtained by throm-
bectomy can be studied in much greater detail than ever 
before. Recent studies have been taking this approach 
to shed light on how in vivo thrombus structures relate 
to thrombosis in different vascular beds. In this review, 
we will summarize the main findings from these studies, 
their technological aspects, associations with disease, 
insights from animal models, and highlight key areas for 
future research.
MAJOR THROMBUS COMPONENTS
Formation of thrombi leads to vessel occlusion or the 
generation of emboli that block blood vessels further 
downstream, resulting in MI, AIS, or pulmonary embo-
lism (PE). Principal components of thrombi include fibrin, 
platelets, red blood cells (RBCs), leukocytes, and neu-
trophil extracellular traps (NETs). However, the relative 
contribution of each component differs between throm-
bus location and disease pathology. Below we discuss 
each component and how they contribute, followed by 
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Fibrin(ogen)
Fibrinogen is a 340 kD glycoprotein that circulates in 
blood at 2 to 5 mg/mL.2 When coagulation is triggered, 
thrombin cleaves fibrinogen into fibrin that polymerizes 
into a network of fibers,3 stabilizing blood clots. Fibrin is 
a major contributor to thrombi, with changes in its struc-
ture known to affect clot formation, stability, and break-
down. High thrombin concentrations lead to dense fibrin 
networks that are relatively resistant to fibrinolysis.2 Pre-
vious in vitro studies have linked changes in fibrin clot 
structure,1 viscoelastic properties,4 and hypofibrinoly-
sis5 to thrombosis. However, despite the consistent link 
between in vitro clot structure and thrombosis, it is still 
unclear whether comparable changes are reflected in the 
structure of in vivo thrombi. Early studies that explored in 
vivo thrombi used angioscopy to evaluate macroscopic 
properties. Two main types of thrombi were observed in 
patients with acute coronary syndromes, white and red.6 
Histology indicated that white thrombi from patients with 
ST-segment–elevation MI (STEMI) were mainly com-
posed of fibrin, whereas red thrombi were mainly com-
posed of RBCs.7 Thrombi from patients with STEMI that 
are resistant to fibrinolysis are characterized by dense 
fibrin and higher contents of platelets and VWF (von Wil-
lebrand factor).8 These studies highlight how fibrin con-
tribution to thrombi varies between disorders and may 
impact disease progression and outcome. In vitro studies 
have shown how clots with increased fibrin demonstrate 
greater friction,9 suggesting these thrombi are stickier. 
This could be an important factor in clot stability, emboli-
zation, and thrombectomy.
Recent findings presented a new structural feature 
of fibrin in clots. Instead of forming 3-dimensional fiber 
networks, fibrin molecules align into continuous films 
forming a protective layer across the surface of clots, 
providing protection against infection.10 There is evidence 
that fibrin also forms films within the vasculature. Images 
of intraluminal thrombi from patients with abdominal aor-
tic aneurysm show signs of fibrin film both within and 
on the clot surface (Figure 1). Clots from murine venous 
thrombosis models also demonstrate the presence of film 
(Figure 1). In agreement with these unpublished findings, 
many studies have presented evidence of film in thrombi. 
Scanning electron microscopy (SEM) micrographs of 
thrombi from patients with PE,11 AIS,12 or MI13 showed 
fibrin film in these thrombi. A recent study showed struc-
tures surrounding thrombi removed from patients with 
AIS that had similar properties to fibrin films, which these 
authors called a shell, and which slowed thrombolysis.14 
Combined with the findings that fibrin content varies in 
thrombi, these data indicate an important role for fibrin 
in thrombus characteristics, influencing stability, embo-
lization, and breakdown. Further research is needed to 
understand how fibrin content in thrombi influences dis-
ease onset, progression, and outcome, and how previ-
ously described changes in in vitro fibrin clot structure 
relate to in vivo thrombus structure.
Platelets
Platelets are an attractive target for antithrombotic treat-
ment. Activated platelets provide negatively charged 
membrane surfaces that are essential for assembly of 
the prothrombinase and tenase complexes.15 Platelets 
form different populations during clot formation, includ-
ing procoagulant platelets which support thrombin gen-
eration and fibrin formation, and aggregating platelets 
involved in initial clot formation and contraction.16 Within 
thrombi, strongly activated platelets localize in the inner 
core, while discoid and quiescent platelets localize to the 
exterior.16 Clot contraction is mediated by aggregating 
platelets binding fibrin fibers via αIIbβ3.
16 Procoagulant 
platelets show a balloon-like structure, exposing phos-
phatidylserine on the surface to generate thrombin in 
Nonstandard Abbreviations and Acronyms
AIS acute ischemic stroke
LSCM laser scanning confocal microscopy
MI myocardial infarction
MRI magnetic resonance imaging
NETs neutrophil extracellular traps
PAI-1 plasminogen activator inhibitor-1
PE pulmonary embolism
RBCs red blood cells
SEM scanning electron microscopy
STEMI  ST-segment–elevation myocardial 
infarction
TF tissue factor
tPA tissue-type plasminogen activator
VTE venous thromboembolism
VWF von Willebrand factor
Highlights
• Thrombosis occurs when a thrombus forms inside 
blood vessels disrupting blood flow.
• Thrombi obtained from myocardial infarction are 
composed of mainly fibrin and other components, 
including platelets, red blood cells, leukocytes, and 
cholesterol crystals.
• Thrombi from patients with acute ischemic stroke 
are characterized by red blood cell- and platelet-rich 
regions.
• Thrombi from patients with venous thromboembo-
lism contain mainly red blood cells and fibrin with 
some platelets and leukocytes.
• Thrombus structure and composition are important 
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situ.17 In addition, platelets promote thrombus growth 
and propagation through GPVI binding to fibrin.18,19 More 
studies are needed to investigate the temporal and mor-
phological contribution of platelets to the architecture of 
thrombi obtained ex vivo.
Leukocytes
Leukocytes contribute significantly to clot formation and 
are found in both arterial and venous thrombi.20,21 Leu-
kocytes bind fibrin via integrin receptor αMβ2 (Mac-1), 
which supports the inflammatory response.22 Neutro-
phils, the most abundant leukocyte in circulation, release 
matrix metalloproteinases, platelet-activating factor, 
cathepsin G, and elastase.23,24 These molecules can 
impact coagulation via a number of mechanisms, includ-
ing activation of coagulation factor V, factor VIII, and 
factor X,25–27 activation and aggregation of platelets,28 
degradation of antithrombin III and proteolytic cleavage 
of TF (tissue factor) pathway inhibitor.29,30 Monocytes are 
a major source of intravascular TF expression and pro-
vide a membrane surface for coagulation initiation in a 
number of conditions.25,31 TF is also expressed by neutro-
phils in animal models.32 Some studies report TF expres-
sion in neutrophils and eosinophils,33,34 but other studies 
fail to detect TF expression in granulocytes.35,36 Some of 
these discrepancies may be attributed to direct transfer 
of TF from monocytes to granulocytes.37
Neutrophil Extracellular Traps
A key mechanism by which neutrophils contribute to 
thrombus composition involves generation of NETs. 
NETs are formed by neutrophils extruding DNA, histones, 
and granular proteins in response to microbial invasion, 
inflammatory stimuli, or activated platelets.38 Increasing 
evidence shows that NETs are associated with thrombo-
sis.39,40 NETs are thought to trigger coagulation via the 
intrinsic pathway, with DNA acting as scaffold for con-
tact assembly triggering thrombin generation.38 Heparin 
binds histones in NETs resulting in their breakdown and 
reduction of thrombosis.41,42 One study suggested that 
neutrophil DNA or histones can trigger coagulation, but 
not NETs, due to histone-histone and histone-DNA inter-
actions.43 NETs act as scaffold for platelet aggregation, 
further promoting thrombus development, and there is 
evidence they increase resistance to thrombolysis.38,41,42 
The relationship between NETs and thrombosis and the 
underlying mechanisms remain of key interest since 
NETs are present in both arterial and venous thrombi.39 
Extracellular DNA has been observed in platelet-rich 
areas of AIS thrombi but not in RBC-rich regions.44 How-
ever, NET-like structures were found in RBC-rich regions 
of murine venous thrombi,39 highlighting the need for fur-
ther research into the role and localization of NETs.
Red Blood Cells
Recent studies have indicated that RBCs play a more 
functional role in clot structure and function than previ-
ously thought. FasL/FasR (CD95) receptor ligand inter-
actions between RBCs and activating platelets have been 
shown to lead to phosphatidylserine exposure on both 
platelets and RBCs and to platelet degranulation, contrib-
uting to thrombus formation.45,46 RBCs have been shown 
to support thrombin generation via the meizothrombin 
pathway.47 High hematocrit promotes accumulation of 
platelets at vascular injury sites by pushing platelets from 
the blood vessel center to the vessel wall.48 RBCs reten-
tion within venous thrombi is mediated by factor XIII, sug-
gesting that targeting factor XIII to reduce RBCs contents 
could be a therapeutic approach in venous thrombus as 
Figure 1. Fibrin biofilm in thrombi.
A and B, Film structures in thrombi extracted from patients with abdominal aortic aneurysm. A, Fibrin film covering the thrombus (arrows). B, 
Film transitioning from film to fibers (arrows) and film lining channels traversing the thrombus (asterisk). C–F, Thrombi from murine thrombosis 
model (FeCl3 injury of the inferior vena cava) after perfusion/fixation. C, Small thrombus showing partial film coverage (arrows). D, Film covering 
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less RBC content may limit thrombus mass and stabil-
ity.49 RBCs are normally biconcave, however, recent stud-
ies show that RBCs adopt an alternative structure during 
thrombosis called polyhedrocytes.50 Forces generated by 
platelets pulling on fibrin fibers lead to clot contraction, 
compressing RBCs together, forcing them into a polyhe-
dral structure.50 Polyhedrocytes have been detected in 
thrombi from patients with STEMI.50 Other studies indi-
cate that polyhedrocytes are present in 20% to 31% of 
thrombi from patients with MI.51,52 Polyhedrocytes are also 
found in venous thrombi, pulmonary emboli, and cerebral 
thrombi.53,54 RBCs in clots affect fibrinolysis55 and alter clot 
mechanical properties.56 Furthermore, disorders such as 
sickle cell disease make RBCs rigid,57 reducing thrombus 
permeability.58 RBC-rich thrombi contain more inflamma-
tory cells than other thrombi and associate with increased 
thrombus burden and impaired reperfusion in patients with 
STEMI.59 Altogether, 2 key mechanisms by which RBCs 
influence thrombosis are the formation of polyhedrocytes 
and the generation of additional thrombin. Better under-
standing of the mechanisms underpinning polyhedrocyte 
formation may lead to new treatments of thrombosis.
Other Components
VWF, produced by megakaryocytes and endothelial cells, 
stabilizes factor VIII and mediates platelet adhesion, 
thereby supporting thrombosis.60 VWF has been detected 
in ex vivo thrombi from patients with MI and AIS.14,61 
While the role of VWF in thrombosis through platelet 
activation and thrombin generation is well characterized, 
its presence and role(s) in thrombi require further inves-
tigation. The fibrinolysis pathway also plays a central role 
in thrombosis. tPA (Tissue-type plasminogen activator) 
converts plasminogen to plasmin, a primary fibrinolytic 
protease.1 tPA and its inhibitor, PAI-1 (plasminogen acti-
vator inhibitor-1), have been detected in thrombi from 
patients with MI.8 PAI-1 and protease nexin-1 have also 
been detected in AIS thrombi.14 Variation in fibrinolytic 
proteins and their inhibitors incorporated in thrombi may 
impact on resistance to therapeutic thrombolysis. Finally, 
cholesterol crystals are present in thrombi obtained from 
patients with MI which were mainly derived from plaque 
rupture.62 The role of cholesterol crystals in thrombi is 
unknown and requires further study.
METHODOLOGIES TO INVESTIGATE 
THROMBUS STRUCTURE
Techniques to investigate thrombus structure have their advan-
tages and limitations (summarized in the Table). SEM has been 
used in several studies.52,62,63 It offers high-resolution images 
and visualization of major thrombus components, providing 
descriptive and semiquantitative data.52,62 This enables identifi-
cation of thrombus components, such as polyhedrocytes50 and 
fibrin fibers or films.10 SEM supports the analysis of platelet 
morphological alterations, such as aggregation and pseudopod 
formation.70 In addition, SEM is very useful for the analysis of 
fibrin properties within a thrombus, such as fibrin coverage area 
and fibrin fiber diameter. However, NETs are structurally dif-
ficult to differentiate from fibrin using SEM,71 highlighting the 
need for combining SEM with other methods using specific 
labeling such as correlative light and electron microscopy, laser 
scanning confocal microscopy (LSCM), or immunohistochemis-
try to confirm the nature of some of the components analyzed.
Once thrombi are prepared for SEM no further analysis (eg, 
histology) can be performed.62,63 Identification of components is 
based on morphological appearance, without specific staining. 
Furthermore, limited 3-dimensional information is obtained by 
SEM. SEM may induce artifacts due to sample processing, fixa-
tion and dehydration. Nevertheless, SEM procedures have been 
refined to keep artifacts to a minimum, and in most cases, neg-
ligible. In contrast, LSCM provides 3-dimensional images in fully 
hydrated conditions.5,10 Fluorescent antibodies can be used to 
label specific proteins, allowing for identification of components. 
However, extracted thrombi need to undergo fixation and chemi-
cal clearing before LSCM imaging.72 Resolution is lower than SEM 
and only labeled components are detected with a finite number of 
fluorophores used at once. RBCs within a thrombus may hinder 
optical access to the inside of the clot and thus the collection of 
deep, high-resolution 3-dimensional images by LSCM.72 New opti-
cal clearing methods may need to be explored to produce a suit-
ably transparent thrombus to allow for deep imaging of thrombi at 
the micrometer scale.72 This method could be effective for imaging 
the thrombus structure of patients. LSCM and SEM can each be 
used sequentially on the same sample, but both are expensive and 
time consuming. Correlative light SEM may provide future oppor-
tunities and new developments in the field through matching con-
focal and electron imaging of the same thrombus area.73
Immunohistochemistry has been used to identify specific 
components in thrombi,44,64 via sectional analysis of thrombi with 
a range of resolutions (nm-µm). Recent developments allow 
improved imaging of thrombi and their constituents.39 However, 
despite analysis of sections, mostly 2- rather than 3-dimensional 
information has so far been obtained. Furthermore, the prepara-
tion of thin sample slices may damage the sample to be ana-
lyzed. A combination of imaging techniques is recommended to 
compare high-resolution methods such as SEM with methods 
that allow specific staining, such as immunohistochemistry and 
LSCM. Noninvasive, sensitive, and specific imaging techniques, 
including magnetic resonance imaging (MRI) and positron-
emitted tomography, have also been used to study thrombus 
composition in patients and animal models.65,66 Imaging of AIS 
thrombi revealed information about clot length, clot density, and 
clot burden score.67 Other studies used proteomic approaches to 
identify thrombi constituents.68,69 Correlating thrombus proteome 
to clinical features could be useful for AIS cause identification, 
which may help selecting appropriate treatment.74
THROMBUS COMPOSITION BY 
PATHOLOGY
Since the development of thrombectomy and other endo-
vascular approaches including balloon angioplasty, endo-
vascular thrombolysis, and stenting, mortality of patients 
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substantially. With the advent of thrombectomy new 
opportunities have emerged to investigate pathological 
differences in thrombi extracted from patients. Several 
studies have assessed thrombus composition using a 
combination of SEM, LSCM, and immunohistochemistry 
(summarized in Figure 2).
Venous Thromboembolism
VTE is caused by thrombi in the deep veins of the limbs, 
which can travel to the lungs causing PE. VTE is trig-
gered by 3 fundamental mechanisms, endothelial dys-
function, altered blood flow, and hypercoagulability, also 
called Virchow Triad.75 Data on thrombi obtained by 
Table. Methods Used to Investigate Thrombus Structure
Techniques Advantages Limitations References
Scanning electron microscopy •  High-resolution imaging •  Surface imaging, with limited 3D information Zalewski et al52 and Sil-
vain et al,62,63
•  Detailed observation of major compo-
nents
•  Descriptive or semiquantitative results
•  Further sample processing limited
•  Time consuming
Laser scanning confocal micros-
copy
•  3D imaging •  Detection of limited number of labeled compo-
nents only
Collet et al5 and Macrae 
et al10
•  Component-specific labeling •  Time consuming
(Immuno)histochemistry •  Specific staining of target components •  Detection of stained components only Staessens et al44 and 
Marder et al64
•  Limited analysis (sections rather than whole clot)
•  Time consuming
Imaging (eg, MRI/PET) •  Noninvasive •  No observation of individual cells, proteins or 
detailed clot structure
Blasi et al,65 Oliveira and 
Caravan,66 and Huang 
et al67
•  Determination of thrombus length, den-
sity and burden score
•  Low thrombus resolution
•  Sensitive/specific targeting of thrombus 
components
Proteomics •  Identification of all protein content •  No provision of components quantification or 
distribution
Alonso-Orgaz et al68 and 
Muñoz et al69
3D indicates 3-dimensional; MRI, magnetic resonance imaging; and PET, positron-emitted tomography.
Figure 2. Thrombus composition in myocardial infarction (MI), acute ischemic stroke (AIS), venous thrombosis (VT), and 
pulmonary embolism (PE).
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thrombectomy from patients with VTE is limited. A single 
case study showed that an embolus from a PE patient 
was composed of fibrin with RBCs and a small number 
of platelets.11 SEM indicated structures similar to fibrin 
film covering the embolus, although these were not com-
mented on at the time. In another case-study of a patient 
with chronic venous insufficiency, thrombi were aspi-
rated from the right atrium and pulmonary arteries. The 
atrial thrombus contained mostly RBCs, with platelets, a 
small number of leukocytes, and a random arrangement 
of fibrin fibers. In comparison, more fibrin and platelets 
aggregates were observed in pulmonary thrombi, with 
fibrin fibers arranged along the vessels.76 An earlier 
review showed a venous thrombus with densely packed 
RBCs resembling polyhedrocytes interspaced by fibrin.77 
Furthermore, an autopsy study examined venous thrombi 
and pulmonary emboli from 8 patients who died from 
VTE, showing that all thrombi and emboli contained 
fibrin, RBCs, VWF, and GPIIb/IIIa.78
A study of the composition and mechanical properties 
of 2 emboli obtained from a patient with PE showed that 
their structure was heterogeneous, with one embolus 
containing more RBCs but less fibrin than the other.79 
Cyclic compression analysis showed that the fibrin-rich 
embolus exhibited a higher stress response than the 
RBC-rich embolus. These findings indicate that throm-
bus composition impacts on mechanical properties, which 
may affect embolization, endovascular removal by throm-
bectomy and thrombolysis. A recent study compared 
thrombi from patients with STEMI (n=45) and venous 
thrombi (n=25) both obtained by open thrombectomy to 
pulmonary emboli from autopsies (n=10).53 All arterial 
thrombi were composed of fibrin followed by platelets, 
while major components of venous thrombi and pulmo-
nary emboli were RBCs followed by fibrin. However, pul-
monary emboli showed more fibrin and fewer RBCs than 
venous thrombi.53 In addition, RBCs in pulmonary emboli 
were present in the form of polyhedrocytes. The structure 
of fibrin in venous thrombi was heterogenous, including 
fibers, sponge, and bundles, while most of the fibrin in 
pulmonary emboli were fibers.53 The mechanisms behind 
these differences in composition are not known. It is pos-
sible that thrombus areas with a particular composition 
embolize, or emboli may change composition after they 
embolize and lodge in the pulmonary circulation. In view 
of the relative paucity of data, further studies investigat-
ing thrombus composition in VTE are required, however, 
thrombectomy is not normally a treatment of choice in 
VTE. Future developments in imaging and in vivo models 
are needed to progress this area of research.
Animal models of VTE show changes in throm-
bus composition and susceptibility to fibrinolysis over 
time.80,81 However, research on thrombus maturation in 
humans is limited. An autopsy study has used immuno-
histochemistry and LSCM to examine the thrombus com-
position in 140 cases of subjects who died due to PE.82 
Upon autopsy, thrombi were classified into phase 1 (first 
week), phase 2 (second to eighth week) and phase 3 
(older than 2 months). Phase 1 thrombi were composed 
of fibrin, platelets, agglomerated RBCs, and leukocytes. 
There was no interaction between the thrombus and the 
vascular endothelium. In phase 2, thrombi showed pen-
etration of fibroblasts, and endothelial sprouting became 
apparent. Furthermore, macrophages containing pre-
dominantly hemosiderin, RBCs and fibrinous transforma-
tion were observed with nuclear debris of leukocytes. In 
phase 3, the thrombi became hyalinized, and few leuko-
cytes were present interspersed by fiber-rich and cell-
deficient connective tissue.82
A catherization study analyzed thrombi extracted from 
17 patients with deep vein thrombosis and 10 patients 
with PE. Thrombi were classified into stage 1 (0–1 day 
old; composed of fibrin, platelets, RBCs, and neutrophils), 
stage 2 (1–3 days old; acute thrombi containing inflam-
matory cells without cellular organization), stage 3 (4–7 
days old; thrombi exhibiting cellular growth, including 
smooth muscle cells and endothelial cells), and stage 
4 (>7 days old; healing thrombi characterized by lay-
ers of smooth muscle cells, proteoglycan depositions, 
and endothelial filtration). All thrombi contained fibrin, 
RBCs, platelets, and inflammatory cells, and thrombi 
were generally younger in PE than patients with deep 
vein thrombosis.83 Based on the relatively scant literature 
on thrombus maturation in VTE, further clinical and pre-
clinical research is necessary to gain clearer insights into 
how thrombi change over time.
Myocardial Infarction
MI is caused by rupture of an atherosclerotic plaque 
resulting in thrombosis.84 Thrombi extracted from 
patients with STEMI (n=44) were analyzed by SEM and 
contained mainly fibrin (60%), with the remainder (40%) 
composed of platelets, RBCs, cholesterol crystals, and 
leukocytes.62 Another study of sudden cardiac death 
(n=23) and STEMI (n=98) showed similar results, with 
no difference observed between these 2 groups.63 A 
separate study also showed that the major component 
of STEMI thrombi (n=40) was fibrin (49.1%), with other 
components, including RBCs (24.2%), platelets (11.6%), 
and leukocytes (3.7%).85 Immunobiological analysis of 
MI thrombi showed the presence of monocytes, neu-
trophils, and lymphocytes.86 Acute MI thrombi (n=29) 
analyzed by immunohistochemistry showed that thrombi 
contained fibrin, platelets, RBCs, and leukocytes.87 Other 
immunohistochemistry analysis of occlusive MI thrombi 
(n=15) revealed the presence of fibrin, glycoprotein IIb/
IIIa, TF, and VWF.61 Coronary arteries from patients with 
MI (n=31) examined postmortem showed that thrombi 
associated with ruptured plaques have more fibrin (74%) 
than platelets (35%), while thrombi associated with 
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(51%). Tissue factor contributed more to thrombus for-
mation in plaque rupture than erosion.88 Antimicrobial 
peptides released by leukocytes have been shown to 
contribute to platelet activation and thromboinflamma-
tion in human and murine models of MI.89
Thrombi surfaces contain more fibrin and platelets, 
and fewer RBCs, than their inner parts.52 Inner parts of 
STEMI thrombi are rich in polyhedrocytes,50–52 providing 
a densely packed structure resistant to fibrinolysis. A 
comparison between thrombi from patients with STEMI 
and peripheral arterial disease indicated reduced fibrin 
content, fibrin fiber diameter, and fibrin/platelet ratios in 
the coronary thrombi.90 A retrospective study exploring 
fibrin films in thrombi from patients with STEMI showed 
that fibrin film was detected on ≈15% of thrombi.13 Film 
was not detected in all thrombi due to heterogeneity of 
thrombi and could also have been missed due to the 
study being retrospective.
Ischemic time has been reported to affect the com-
position of thrombi (Figure 3). Silvain et al62,63 demon-
strated that as ischemic time increased the amount of 
fibrin increased while platelets decreased in STEMI 
thrombi.62,63 STEMI thrombi (n=40) retrieved over 12 
hours after the onset of symptoms showed more fibrin 
than thrombi retrieved within 3 hours.85 Correspond-
ingly, RBCs decreased over time, but no associations 
were found for leukocyte and platelet counts.85 STEMI 
thrombi (n=65) retrieved >6 hours after onset of symp-
toms showed more compact fibrin network than thrombi 
retrieved <3 hours.86 With increasing time after symp-
tom onset, platelet numbers decreased, and lymphocyte 
numbers increased.86 Polyhedrocyte formation increased 
with ischemic time in thrombi from patients with MI.51 
Taken together, these findings indicate that thrombus 
composition may change over time after initial vessel 
occlusion in STEMI. Such changes in thrombus com-
position may have important implications for mechani-
cal thrombectomy, thromboaspiration, and thrombolysis. 
Further research is required to understand the mech-
anisms through which thrombi change structure, for 
example, through thrombus component reorganization 
or clotting-lysis cycles.
Acute Ischemic Stroke
AIS, the most common type of stroke, is caused by 
thrombosis in the cerebral circulation. AIS thrombi are 
due to atherosclerosis or cardiac embolism and result 
in disrupted blood flow in the brain and subsequent 
neurological disorder.91 A recent study showed that AIS 
thrombi (n=177) obtained by thrombectomy contain 2 
distinct structural areas, platelet- and RBC-rich regions, 
that interspersed each other throughout the thrombi.44 
Platelet-rich regions contained dense fibrin, platelets, 
VWF, leukocytes, and extracellular DNA. RBC-rich 
regions, however, were composed of RBCs and fibrin, 
while bordered by platelets and leukocytes.44 Another 
recent study showed that AIS thrombi (n=199) pre-
sented with a surface structure that resembles fibrin 
films.14 They referred to this as an outer shell, mainly 
composed of fibrin, that slowed thrombolysis. One com-
plication in patients with AIS is thrombus migration, 
Figure 3. Ischemic time and thrombus composition in patients with ST-segment–elevation myocardial infarction (STEMI).
The amounts of fibrin, polyhedrocytes, and lymphocytes increase with ischemic time, while platelet and red blood cell (RBC) loads decrease. 
Note: the ratios of components within each thrombus (individual graph), as well as the ratios of components between both thrombi (between 













Alkarithi et al Thrombi Structure and Vascular Disease
8  September 2021 Arterioscler Thromb Vasc Biol. 2021;41:00–00. DOI: 10.1161/ATVBAHA.120.315754
whereby the clot travels downstream in the cerebral vas-
culature, resulting in worse outcomes. Migrating thrombi 
contained more RBCs and less fibrin/platelets than 
stable thrombi.91 This may relate to previous findings 
that RBC-rich clots are less sticky.9 In addition, fibrin 
anchors clots to the site of vascular lesion, thus prevent-
ing embolism in animal models.92
Histological analyses showed that AIS emboli (n=25) 
were composed of platelets and fibrin with RBC-rich 
regions and leukocytes, including monocytes and neutro-
phils.64 A further histological study of AIS thrombi (n=37) 
showed that inflammatory T cells and monocytes were 
associated with RBC-rich clots, while VWF was associ-
ated with fibrin-rich clot.93 Early signs of vessel damage, 
including hyperdense middle cerebral artery sign and 
blooming artifact by computed tomography and MRI, indi-
cate presence of thrombus.94 Thrombi from hyperdense 
middle cerebral artery sign and blooming artifact patients 
were RBC rich, while thrombi lacking these signs were 
fibrin rich.94 AIS thrombi (n=40) have been histologically 
categorized into early phase (RBC proportion dominant 
or equal to fibrin) and late phase (fibrin dominant and 
organized fibrin). Presence of hyperdense artery sign 
has been associated with early phase thrombus.95 Cere-
bral thrombi from patients with AIS (n=41) were com-
posed of areas with many RBCs, mainly polyhedrocytes, 
and fibrin mixed with platelets with the presence of few 
leukocytes. There was no significant difference in RBC 
content between patients with cardioembolic and ath-
erothrombogenic stroke. However, fibrin content was 
higher in patients with cardioembolic than patients with 
atherothrombogenic stroke.54 Similarly, previous stud-
ies showed that AIS of cardioembolic cause was asso-
ciated with fibrin-rich thrombi while noncardioembolic 
thrombi (atherothrombogenic and cryptogenic thrombi) 
were associated with RBC-rich thrombi, however, the 
mechanisms behind these differences are unknown.96 
Together, these studies indicate that thrombus composi-
tion changes by AIS cause, with RBC-rich thrombi asso-
ciating with thrombus migration and fibrin-rich thrombi 
associating with stable and late phase thrombosis. How-
ever, one autopsy study found that the RBC content in 
cardioembolic thrombi was higher than in atherothrom-
botic stroke, indicating that the differences by cause 
may be more nuanced.97 The association of these types 
of thrombi with disease outcome and treatment such as 
thrombectomy and thrombolysis deserve further study, 
including detailed analysis of the composition of these 
thrombi in terms of other components using state-of-
the-art methodologies.
Therapeutic Implications
Thrombosis treatments include the use of antiplatelet, 
anticoagulant, and fibrinolytic agents. Antiplatelets are 
generally used to prevent and treat arterial thrombosis,98 
which is caused by atherosclerotic plaque rupture that 
leads to collagen exposure followed by platelet aggre-
gation and thrombus formation.99 Treatments targeting 
platelets appear effective in this setting as platelets have 
an important role in arterial thrombus growth.99 How-
ever, venous thrombosis which occurs under low shear 
stress and is largely driven by a coagulation imbalance is 
treated with anticoagulants since venous thrombi contain 
an abundance of fibrin.98,99 Fibrinolytic agents may be 
used in both arterial and venous thrombosis settings.98
Many trials have indicated that a combination of anti-
coagulant and antiplatelet treatments could be an effec-
tive strategy for mitigating cardiovascular disease.100 In 
one study, patients with acute coronary syndrome were 
treated with either a combination of antiplatelets agents 
and rivaroxaban (an activated factor X inhibitor) or a pla-
cebo. The use of rivaroxaban reduced instances of car-
diovascular death, MI, and AIS; however, it also increased 
the risk of major bleeding, including intracranial hemor-
rhage.101 In another study, coronary syndrome patients 
were treated with either aspirin, a combination of rivarox-
aban and aspirin, or rivaroxaban without aspirin. Among 
these groups, the combination of rivaroxaban and aspirin 
yielded the best cardiovascular outcomes but was asso-
ciated with a moderate increase in bleeding risk.102
Therapeutic fibrinolysis is centered around plas-
minogen into plasmin conversion in the thrombus using 
tPA or tPA analogues.103 Increasing evidence indicates 
that thrombolysis may be facilitated by targeting addi-
tional components in the thrombus other than fibrin. 
For instance, NETs that are present in venous and 
arterial thrombi and have been shown to delay throm-
bolysis by tPA could be a potential therapeutic target 
using DNases.104,105 Furthermore, the effectiveness of 
thrombectomy could be influenced by thrombus com-
positions. For example, in patients with AIS, it has been 
shown that RBC-rich thrombi are associated with suc-
cessful recanalization,106,107 require fewer passes and 
lower procedure time than fibrin-rich thrombi.96 Thus, 
analysis of the thrombus structure in cardiovascular 
patients could aid the development of new thrombolytic 
or antithrombotic strategies.
INSIGHTS FROM ANIMAL MODELS
Animals models are essential for the study of thrombosis 
pathophysiology or the role of drugs in thrombosis pre-
vention.108–110 Studies discussed below provide insight in 
the composition of arterial or venous thrombi.
Animal Models of Arterial Thrombosis
An early study by Randall and Wilding111 showed that 
thrombi from rabbits induced by electrical stimulation 
of the wall of carotid arteries were platelet rich.111 Clots 




 http://ahajournals.org by on July 19, 2021
BRIEF REVIEW
 - VB
Alkarithi et al Thrombi Structure and Vascular Disease
Arterioscler Thromb Vasc Biol. 2021;41:00–00. DOI: 10.1161/ATVBAHA.120.315754 September 2021  9
thrombolysis of platelet-rich thrombi induced by trans-
luminal electrode was impaired compared with that of 
fibrin-rich thrombi induced by intraluminal copper wire 
and that reocclusion under antiplatelet therapy was 
more frequent for fibrin-rich thrombi.112 Complementary 
to this, studies in rabbit femoral arteries showed that 
RBC-rich thrombi triggered by thrombin infusion were 
more prone to thrombolysis than platelet-rich thrombi 
induced by everted artery graft, with platelets provid-
ing a source of PAI-1.113 A later study in rat carotids 
showed that platelet-rich thrombi (formed by photo-
chemical injury) were more prone to embolization caus-
ing cerebral infarcts, than fibrin-rich thrombi (formed 
by balloon catheter denudation).114 These studies indi-
cate an important role for thrombus composition in 
the severity of thromboembolic diseases. FeCl3 injury 
of rat carotid arteries showed initial platelet clumping 
on the denuded endothelium, while occlusive thrombi 
consisted of RBCs and leukocytes tightly packed by a 
fibrin mesh, with tightly adhered platelets at the anterior 
side, highlighting heterogeneity of arterial thrombi.115 A 
pig carotid artery thrombosis model induced by balloon 
angioplasty showed that thrombi were heterogenous in 
the first 24 hours, including fibrin-rich and platelet-rich 
areas, and sporadic RBCs and neutrophils. Fibrin-rich 
areas were found at the thrombus and vessel wall inter-
face. At day 1, thrombi consisted of granulated platelets, 
cellular debris, and compacted fibrin, while at 2 weeks, 
connective tissue was detected alongside cellular 
debris and unresolved fibrin. Over 3 to 9 weeks, thrombi 
became more fibrous, containing new blood vessels.116 
This model may be relevant to human pathophysiology, 
particularly about thrombus composition and changes 
in chronic coronary occlusion.116,117
Occlusive thrombi from rabbit arteries by balloon 
angioplasty stained positive for glycoprotein IIb/IIIa, 
fibrin, VWF, and TF,118 in agreement with human stud-
ies.119 The neointima could play a role in thrombus com-
position and size due to tissue factor expression on the 
smooth muscle cell and macrophage-rich neointima, 
while small, platelet-rich thrombi formed on normal 
intima.120 A recent study indicated that mouse carotid 
artery thrombi triggered by FeCl3 were similar in compo-
sition when compared with human coronary thrombi, as 
both were heterogeneous with compact cell-rich regions, 
and less dense areas with fewer cells. NETs were present 
in both human and murine thrombi, with similar NETs to 
leukocyte ratio. Inhibition of NETs resulted in decreased 
thrombosis and reduced infarct size.121 Staining was tar-
geted at particular components, and RBCs were partly 
overlooked in this study.
Human arterial thrombi mainly result from atheroscle-
rosis and subsequent atherosclerotic plaque rupture, 
which rapidly generates a clot leading to MI and AIS. 
However, in general, most animal models of atheroscle-
rosis do not develop thrombosis due to plaque rupture.122 
Triggering thrombus formation, for example, by FeCl3 
injury only replicates the final stages of atherothrombotic 
disease.123 Nevertheless, FeCl3 or needles have been 
used to induce thrombus formation in atherosclerosis-
relevant models (eg, mice deficient in apolipoprotein 
E).124–126 Analysis of the corresponding thrombi composi-
tions in relevant models for atherosclerosis may provide 
new insights in thrombus structure in the context of car-
diovascular disease. Future studies should focus on the 
role of RBCs in addition to other clot components, as well 
as address questions regarding thrombus heterogeneity, 
composition, and their role in outcomes and treatment.
Animal Models of Venous Thrombosis
McGuinness et al127 showed that 1-day old thrombi gen-
erated after stenosis of rat inferior vena cava consisted 
of platelets, RBCs, leukocytes, and fibrin, with neutrophils 
being the main leukocyte. Monocytes located initially to 
the thrombus edge but were more evenly distributed in 
mature thrombi.127 RBC hyperaggregability induced by 
pluronic F98 treated RBCs correlated with thrombo-
sis occurrence in a rabbit venous thrombosis model.128 
Venous thrombi from baboon iliac veins induced by tem-
porary balloon occlusion contained NETs, with diffuse 
staining of histones and extracellular DNA colocalizing 
with VWF.42 Murine inferior vena cava thrombosis mod-
els showed that NETs are primarily located in RBC-rich 
regions, and colocalized with VWF.39 In agreement with 
NETosis in murine venous thrombi, NETs are also present 
in human venous thrombi obtained by thrombectomy.129
One-day old murine venous thrombi generated by 
combined reduced flow and mechanical endothelial 
injury were RBC-rich in the center with fibrin deposition 
at the periphery as demonstrated by in vivo magnetiza-
tion transfer and diffusion-weighted MRI coupled with 
Martius scarlet blue staining. After 1 week, the central 
part contained RBCs encapsulated in fibrin, while after 
4 weeks thrombi were mainly collagen rich.130 This sug-
gests that magnetization transfer and diffusion-weighted 
MRI are promising for determining thrombus age via its 
composition. Young thrombi were rich in fibrin and RBCs, 
while collagen fibers were present after 1 week after 
FeCl3 injury of rat carotid arteries and femoral veins as 
demonstrated by histology.65 Fibrin peaked after 1 day 
in both venous and arterial thrombi, and venous thrombi 
showed more fibrin than arterial thrombi after a week, 
which was also detected by positron-emitted tomogra-
phy imaging using the fibrin-specific 64Cu-FBP8 probe.65 
Imaging techniques could provide a useful clinical nonin-
vasive tool for detecting thrombus and assessing throm-
bus age. More agents targeting thrombus components, 
mainly fibrin and platelets, have been validated in throm-
bosis models in vivo.131–133 For example, contrast agents 
(microparticles of iron oxide and antibody targeting acti-
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platelets and to monitor thrombolysis by MRI in murine 
arterial thrombi induced by FeCl3.
131 Contrast agent tar-
geting fibrin (EP-2104R) allow MRI detection of fibrin 
content in thrombi and indicated thrombus susceptibil-
ity to thrombolysis in a murine venous thrombosis model 
induced by reducing blood flow and endothelial disrup-
tion.132 Another study used near-infrared fluorescence 
method with fibrin-targeted agent (FTP11-Cy7) in deep 
vein thrombosis models induced by FeCl3.
133
Murine venous thrombosis models provide key 
data on the maturation of venous thrombus. Venous 
thrombi showed changes of thrombus components 
from 2 to 4 weeks, from fibrin-dominant to colla-
gen-dominant thrombi with increasing infiltration 
of inflammatory and mesenchymal cells, and these 
changes were correlated with clot stiffness.80 Due 
to the decreasing fibrin content with age, fibrinolytic 
efficiency reduces with increasing thrombus age in 
murine venous thrombosis models.81
Furthermore, murine inferior vena cava stasis thrombi 
showed areas rich in RBCs, fibrin(ogen), and neutro-
phils, but also contained monocytes and macrophages, 
with leukocytes colocalizing with urokinase plasminogen 
activator. PAI-1 colocalized with platelets, while plas-
minogen and α2-antiplasmin were also present in venous 
thrombi.134 Taken together, these studies indicate that 
thrombus composition changes with age, which likely 
impacts on disease development and treatment.
Choice of Thrombosis Model
Overall, animal models of arterial and venous throm-
bosis help gain valuable information on the content 
and structure of thrombi, with structural characteristics 
similar to human thrombi, thus offering opportunities 
for the development of new diagnostic and therapeutic 
tools. However, there is no single model representing 
all aspects of arterial and venous thrombosis, and at all 
stages of disease, while different methods of thrombosis 
induction can impact thrombus formation timing, com-
position and architecture. Unlike in patients, thrombus 
formation in animal thrombosis models mainly occurs in 
healthy vessels that are acutely injured.109 Developing 
new models that better reflect a diseased environment 
(eg, inflammation and metabolic disease) could further 
support improved characterization of thromboembo-
lism and thrombus structure. Small models (eg, mice) 
showed their value for mechanistic insights into throm-
bosis, particularly in view of the relative ease of genetic 
modifications. However, future studies in larger animal 
models that are anatomically more similar (including the 
vasculature) to humans than smaller species may be 
of interest.109 Therefore, with each model offering its 
own benefits and limitations, it is important to carefully 
select thrombosis models and animal species based on 
study-specific objectives.
CONCLUSIONS
The advent of thrombectomy to treat a growing number 
of diseases heralds a new era in thrombosis research. It 
has enabled the analysis of thrombi from patients in ever 
greater detail, thus learning new information about their 
individual make-up. Careful consideration should be given 
to methods of thrombus composition analysis as each 
has their advantages and disadvantages. Another impor-
tant consideration is to complement component-specific 
staining-based techniques with other methods that pro-
vide structural information at high resolution so that no 
particular thrombus components may be overlooked. 
Based on the literature thus far thrombus composition 
clearly is heterogeneous, varying between thrombotic 
disorders and patients, but even within the same patient 
or thrombus. Areas for future research include the rela-
tionship between thrombus areas and arterial or venous 
thrombosis, and how thrombus composition changes 
over time. Other remaining questions include how throm-
bus composition associates with embolism, effective-
ness of thrombectomy or thrombolysis, and the role of 
polyhedrocytes, fibrin films, or other new structures in 
thrombosis. The development of better techniques to 
investigate thrombus composition, including noninvasive 
imaging methods, and improved animal models that are 
more physiologically relevant to human disease, will fur-
ther be beneficial for future improvements in prevention 
and treatment of this devastating disease.
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